Avidity Biosciences
Agent37 out of 100, Below median. Agent Readiness. Open the scores section.Agent Readiness: 37/100. Below median. Measured by StartupHub.ai. Median 41.Trust81 out of 100, Top 25%. Data Trust. Open the scores section.Data Trust: 81/100. Top 25%. Measured by StartupHub.ai. Median 61.Clinical-stage biotechnology company developing Antibody Oligonucleotide Conjugates (AOCs) for serious diseases.
About
Avidity Biosciences is developing a new class of targeted RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). These AOCs combine monoclonal antibodies and oligonucleotides to deliver therapies to previously inaccessible tissues and target the underlying genetic drivers of diseases. The company is currently advancing programs for rare muscle diseases including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
Listed competitors
Also in this space
Developing carbon dioxide (CO2) reducing technology and converting CO2 and sunlight into organic compounds.
Leveraging the adaptive immune system to diagnose and treat disease.
Shares Biotech, Genomics
A global oncology company developing and commercializing innovative cancer treatments.
Shares Biotech, Genomics
Developing engineered biologics to harness the immune system for disease treatment.
Shares Biotech, Drug Discovery
AI-powered biotechnology company developing RNA therapeutics for genetic diseases.
Shares Biotech, Drug Discovery
Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.
Shares Biotech, Genomics
Key facts
- Website
- aviditybiosciences.com
- Headquarters
- San Diego, United States
- Founded
- 2013
- Employees
- 445
- Total funding
- $495M (IPO)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 9 Oct 2020 | IPO | $280M | |
| 1 May 2020 | Series C | $100M | RTW Investments |
| 1 Mar 2019 | Series B | $100M | OrbiMed |
| 1 Mar 2018 | Series A | $15M | Takeda Ventures |
Tech stack
Detected on aviditybiosciences.com, last scanned 5 Nov 2026. Run your own scan
- Frontend
- jQuery, Bootstrap
- Analytics
- Google Tag Manager
- Cookie consent
- OneTrust
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is Avidity Biosciences trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Avidity Biosciences is 81 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Avidity Biosciences raised?
Avidity Biosciences has raised a total of $495M in funding. The most recent round on record is IPO.
How many employees does Avidity Biosciences have?
Avidity Biosciences has approximately 445 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for Avidity Biosciences:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
